Get started

Stockstobuy

Is Apple Stock Really Worth Investing in January 2025?Strong weekly demand level took control. Expecting a decent reaction. As we enter 2025, the financial landscape is buzzing with excitement and uncertainty. Investors are searching for promising opportunities, and one name that consistently tops the charts is Apple Inc. (NASDAQ: AAPL). Love it or hate it, this tech giant has become synonymous with innovation and growth—drawing both seasoned investors and newcomers alike to its stock like moths to a flame.
NASDAQ:AAPLLong
by AlfonsoMoreno
Quantum Corporation: Major Levels to WatchGood morning, trading family! Quantum Corporation is at a crucial point: Above $34.50: A breakout could push us to $50 or even higher. Below $29: The downside opens up to the $6–$12 range. Stay sharp as these levels could define the next big move. This Sunday, I’m hosting a Master Your Mind Traders Class to help you build a stronger trading mindset and strategy. Seats are limited—send me a DM for details! Kris/Mindbloome Exchange Trade What You See
NASDAQ:QMCO
by Mindbloome-Trading
Micron Technology: Bearish or Ready to Break Out?Good morning, trading family! Micron (MU) is at an important spot right now: If we move lower, I’m watching $97 and $96 as key levels, with potential for more downside. If we hold above $100, there’s room to climb to $102, $103, and $104. A break above $104 could mean a smoother ride higher. I’m also hosting a Master Your Mind Traders Class this Sunday to help you refine your skills and mindset. Want to join? Send me a message for details. Kris/ Mindbloome Exchange Trade What You See
NASDAQ:MU
by Mindbloome-Trading
2
Mangalam Cement: Profitable Long TradeTrade Overview: Mangalam Cement demonstrated a strong bullish move on the 15-minute chart, with all targets (TP1 to TP4) successfully achieved using the Risological Swing Trading Indicator . The trade capitalized on a well-timed entry near ₹919.05, with a stop loss (SL) set at ₹907.45, and hit the final target of ₹994.05, showcasing high accuracy. Key Levels: Entry Price: ₹919.05 Stop Loss: ₹907.45 Take Profits: TP1: ₹933.35 TP2: ₹956.55 TP3: ₹979.75 TP4: ₹994.05 Fundamental Analysis: Recent news supports the price movement: Strong Quarterly Earnings: Mangalam Cement reported a net profit of ₹32.8 million for the September quarter, signaling financial resilience. Improved Profitability: The company has shown consistent growth in quarterly profits, boosting investor confidence. Market Stats: Current Price: ₹1,007.75 (+1.66%) Volume: 142.78K (above average) 52-Week Range: ₹610.30 - ₹1,093.70 Mangalam Cement's robust fundamentals and the Risological Indicator's precision have once again delivered a profitable trade setup.
NSE:MANGLMCEMLong
by ProfitsNinja
JSW ENERGY BREAKOUT LEVELS JSW Energy - Potential Breakout Setup 📈 Analysis: JSW Energy is showing signs of building momentum. The stock is currently testing a key resistance zone at ₹ . If the price breaks above this level, we could see a strong breakout rally. A clean breakout above ₹ would confirm the bullish trend, potentially targeting ₹ in the near term. 🔑 Key Factors to Monitor: Look for an increase in volume as confirmation of the breakout. A close above ₹ on high volume will likely push the stock higher. The RSI is showing strong bullish momentum, suggesting more upside potential. Watch out for any reversal patterns or resistance re-tests after the breakout. 💡 Trade Idea: 📅 Timeframe: Watch for price action over the next few sessions to confirm the breakout. 📌 Disclaimer: This post is for educational purposes and does not constitute financial advice. Always perform your own analysis or consult a professional before making any trades.
NSE:JSWENERGYLong
by jagur_dfo
Suntek realtyFrom the Covid low of 145 zone prices have given a rally for two years and made a high of 590 in Jan'22. From there prices have retraced 50% and made a low of 272 and recovered back to hit new all time high. Prices have made a continuation Head & shoulders pattern whose neckline is 500 zone. Prices have given the breakout the neckline and currently retesting the same. The measured target of the pattern is 950 zone. Prices are likely to continue the uptrend towards 950-1000 zone in the coming months. The key level for the same is 380.
NSE:SUNTECKLong
by TradingSutra
Linde plc | LIN Linde, Timeless Excellence Linde is a timeless business with even better stability than other basic materials businesses. The company works in gases and has a near-unbroken EPS growth record of 8% annually Linde is a market leader, and if you invest in the company, you're investing in the world's largest company for industrial gases. The company was originally a result of a takeover of British BOC in 2006, and again the 2018 merger of Linde and Praxair, a US company. On the macro upside, there was a 1) supportive regulatory framework in the USA and in the EU on green opportunities and hydrogen, 2) the Ukraine invasion was also a key catalyst towards the energy transition, 3) the EU chip acts with €43 billion in supporting funds as well as the United States Chips and Science Act development for a value of approximately $52 billion, and 4) higher needs of specialty gas in EV car. Related to the micro upside, the company is more diversified on a GEO revenue basis and sells different product solutions starting from cylinders to bulk liquid. In addition with a follow-up note titled "Positive News Ahead", we reported Linde's lower cost structure with the Frankfort delisting. Aside from removing the dual listing expenses, we positively view this development because US companies' P/E multiple are usually higher compared to the EU one. To support our MACRO buy case recap, in the second quarter, Linde announced two new projects with Evonik and Heidelberg Materials (both companies covered by our internal team). The company signed a long-term agreement to produce green hydrogen for Evonik in a 9-megawatt alkaline electrolyzer plant in Singapore. With Heidelberg, Linde will build a large-scale carbon capture close to the Lengfurt plant in Germany. As a reminder, cement production is estimated to be responsible for around 7% of global in 2022, APD's earnings per share were at $8.38, and Linde's earnings per share were fairly similar at $8.23. For 2023, Air Products and Chemical EPS guide a midpoint at $11.40 while Linde's EPS is forecasted at $13.65. Looking at the ROCE, in Q4 2022, APD stood at 11.7% and Linde at 13.4%. In the last quarter, APD’s ROCE was flat on the two-year comparison, while Linde’s after-tax ROCE reached 24.0%. While there are some business & regional nuances between the two leading companies (for instance, APD is lacking U.S. packaged gas business), here at the Lab, we believe are more inclined toward Linde, particularly when organic growth has been fairly similar. Cross-checking APD and Linde's last quarter results, we should recall that on a comparable basis, the German player volumes were flat with an average selling price up by 8%. On the other hand, APD increased its volume by 6% with an increase in the average selling price of 8% too. APD adj EBITDA grew by 13% while Linde achieved a plus 11%. However, Linde's EU exposure is greater than APD. Therefore, this is supportive of Linde's bottom line. In numbers, excluding the Engineering divisional performance, Linde's EMEA sales reached $2,177 million and represented 29.72% of the company's total sales. Compared to Q1 2022 number, turnover grew by 10% and was driven by a 13% of cost pass-through increase.
LLong
by moonypto
6
TEVA Pharmaceutical is a BUY?As the excitement around AI continues to wane, concerns about a potential US recession grow, and the risks of a major conflict in the Middle East linger, Teva Pharmaceutical's stock is entering an accumulation phase above $18, signaling strong bullish sentiment. Why Wall Street's bullish in this drug company ? First, on July 31, Teva announced its financial results for the second quarter of 2024, demonstrating that the company remains resilient despite years of investor disappointment following the Allergan Generics acquisition and the loss of Copaxone exclusivity. However, over the past 18 months, under Richard Francis' leadership, the company has shown significant growth, with increasing revenue and profits in its European and US segments, the successful launch of biosimilars and Uzedy, and record sales of Austedo, its blockbuster treatment for certain neurological disorders. Alongside rising sales of generics, Teva has also accelerated the development of innovative medications, which could set new standards in treating schizophrenia and some chronic inflammatory diseases. For instance, on July 25, the company delighted investors by announcing that it had completed patient enrollment ahead of schedule in a Phase 2b clinical trial assessing the efficacy and safety of duvakitug for treating ulcerative colitis and Crohn's disease, driven by strong interest from healthcare professionals and patients. Teva Pharmaceutical's financial performance and 2024 outlook After years of challenges, the Teva revenue exceeded $4 billion once again, reaching $4.14 billion in the second quarter of 2024, a 7.4% year-on-year increase that surpassed consensus estimates by $114 million. Meanwhile, another critical financial metric, earnings per share aka EPS, exceeded my expectations despite rising costs associated with conducting expensive clinical trials for assessing the efficacy of Teva's biosimilars and experimental drugs targeting neurodegenerative and autoimmune disorders. The Israeli company's EPS reached $0.61 for the three months ending June 30, 2024, marking a 27.1% increase from the previous quarter and surpassing analysts' forecasts by six cents. What factors contribute to Teva Pharmaceutical's success? To answer this objectively, it's essential to examine not only the impact of sales from individual medications but also to delve deeper into how effectively the company's management is handling the development of each of Teva's business segments. We'll begin with the United States segment, which significantly influences Teva's financial standing. For the three months ending June 30, 2024, revenue in this segment reached $2.12 billion, reflecting an 11.5% year on year increase and a 22.3% rise from the previous quarter. First, Teva's revenue and profit growth were largely fueled by significant advancements in its generics business, despite facing stiff competition from companies like Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Perrigo (PRGO), and others in the market. In the second quarter, total sales of generic products reached approximately $1.03 billion, marking a 26.6% increase from the previous quarter. What factors led to the recovery of Teva's generics business? The resurgence of Teva's generics business in the U.S. was primarily driven by the launch of an interchangeable biosimilar to AbbVie's Humira (ABBV), rising demand for generic versions of Bristol-Myers Squibb's Revlimid (BMY), a major blockbuster for treating multiple myeloma, the generic version of Novo Nordisk's Victoza (NVO) for type 2 diabetes, and the expansion of its drug portfolio. The soaring sales of Copaxone and the strong performance of Austedo, which I analyzed in detail in a previous article, were also notable. Despite increasing competition in the U.S. tardive dyskinesia therapeutics market from Neurocrine Biosciences' (NBIX) Ingrezza, Austedo's demand continued to grow. Sales of the Austedo franchise reached $407 million in the second quarter of 2024, a 32.1% YOY increase, driven by expanded patient access and the FDA's late May approval of Austedo XR in four new tablet strengths, giving doctors more options for optimizing treatment regimens for adults with tardive dyskinesia and Huntington's disease-associated chorea. I also want to highlight Uzedy, a long-acting formulation of risperidone, as another key contributor to Teva's revenue growth. Although the company launched Uzedy in May 2023 and has not yet disclosed its sales figures, it has been approved for the treatment of schizophrenia. However, as evident from the chart below, the total number of prescriptions has been steadily increasing month over month. Teva Pharmaceutical estimates that its revenue from Uzedy will be around $80 million in 2024, exceeding my expectations by approximately $25 million. Despite ongoing growth in demand for this anti-CGRP migraine medication, its sales amounted to $42 million in the second quarter of 2024, a decrease of 6.7% compared to the previous quarter and 19.2% year-on-year. This decline was primarily due to an increase in sales allowances linked to a one-time event. Now, let's turn our attention to the company's Europe segment, which generates most of its revenue through sales of generics and biosimilars. For the three months ending June 30, 2024, sales in this segment reached approximately $1.21 billion, reflecting a 4.3% year-on-year increase, driven by new product launches and growing demand for Ajovy. However, sales of respiratory medications continue to face challenges due to a decline in cold and flu cases. As anticipated, demand for Copaxone is weakening, not only because of competition from generic versions but also due to the availability of more effective treatments for relapsing forms of multiple sclerosis, such as Bristol-Myers Squibb's Zeposia, Roche Holding's Ocrevus and TG Therapeutics' Briumvi (TGTX). Lastly, let's discuss the International Markets segment, which focuses on commercializing Teva's drugs across 35 countries, including Canada and Japan. In the second quarter, revenue for this segment was $593 million, representing a 2.6% YOY increase. However, the segment's profit dropped significantly to $73 million quarter over quarter, due to declining demand for Copaxone, increased R&D expenses, and higher sales and marketing costs related to the distribution of Austedo in China. The question arises: "Are there any positives?" The short answer is yes. Teva's revenue from generic drugs has been on an upward trend in recent years, with the exception of the fourth quarter of 2023. For the three months ending June 30, 2024, it reached $488 million, marking a 2% increase from the previous quarter. What is driving this sales growth? Despite challenges such as the weakening of foreign currencies like the Japanese yen, ruble, and Chinese yuan against the US dollar, increased competition in Japan, and ongoing inflationary pressures on the pharmaceutical industry, Teva’s management has successfully navigated these obstacles by expanding its medication portfolio and raising prices. Now lets talk about Risks Several risks could negatively impact Teva Pharmaceutical’s investment appeal in the medium to long term. At the end of July, Teva reported financial results for the second quarter of 2024, which not only exceeded analysts' expectations but also reinforced confidence in the effectiveness of the business strategies implemented by CEO Richard Francis. In addition to accelerating the recovery of the company's generics business, boosting sales of Austedo and Uzedy, and launching the Humira biosimilar in May, Teva also raised its full-year 2024 guidance. With a P/E ratio of 6.35x, which suggests the stock is trading at a discount compared to the broader healthcare sector, other positives include the reduction of Teva’s net debt by about $2 billion over the past 12 months, as well as year-over-year growth in gross and operating profits. To understand who truly holds control over Teva Pharmaceutical Industries Limited, it's crucial to examine the company's ownership structure. The largest share of ownership, approximately 69%, is held by institutional investors. This means that this group stands to experience the greatest potential for gains or losses, depending on the company's performance. The company has also accelerated the development of its product candidates under its "Pivot to Growth" program, which aims to strengthen its balance sheet and enhance its investment appeal by expanding its biosimilar portfolio and bringing potential best-in-class drugs for cancer, neurological, and autoimmune disorders to market. So TEVA Pharmaceutical is a BUY? YUP
NYSE:TEVALong
by moonypto
DJT: Will It Break $33.85 or $38.55 First? DJT is at a tipping point, and it could go either way. Here’s what to watch so you’re ready for the next big move. 1) If DJT Drops Below $33.85 If this level breaks, things could get rough. Here’s what might happen: -$28–$26: This is the first stop where the price might chill for a bit. -$10: If the selling gets heavy, this is where we could end up. 2) If DJT Pops Above $38.55 If the bulls take charge, it could be time to ride the wave higher: A break above $38.55 could spark a nice rally and push the price upward. What’s the Plan? -Keep an eye on $33.85 and $38.55—they’re the magic numbers. -Be patient and wait for a clear move before jumping in. If this makes sense, toss me a like or follow. Got questions about DJT or another stock you’re stuck on? Hit me up in the DMs—I’m here to help. And hey, if you’re feeling burned out or stressed about trading, let’s talk. I’m all about helping you find your balance and keeping things sustainable. Chill, stay focused, and let’s catch the next wave together! Kris/ Mindbloome Exchange Trade What You See
NASDAQ:DJT
by Mindbloome-Trading
2
QMCO at a Make-or-Break Moment: 5 Key Levels to Watch Now Morning Trading Family QMCO is approaching a critical crossroads, and the next move could bring some serious action. Let’s break it down with key levels and what they mean for traders. If we break below $65.46 The outlook turns bearish. These are the levels to watch on the way down: $60: First stop. This is where buyers might step in to test the waters. $55: A deeper pullback that could bring more attention from the market. $52: A critical level. If we hit this, it’s time to reevaluate what’s next. If we break above $68.37 This would signal a potential shift in behavior, and the bulls might take over. Here’s what could happen: $70: The next challenge for price to clear. $73: A key level that could act as resistance. Above $73? That’s the green light for a long position. If the price moves past $73, it’s likely that the trend has flipped, and we could see much higher levels. What You Can Do -Keep a close eye on $65.46 and $68.37. These levels are your signals for the next move. -Plan ahead—set stop-loss levels to manage your risk. -Stick to your strategy and don’t rush into trades without confirmation. If you found this helpful, don’t forget to follow, like, or boost this video. Have questions about other charts or feeling stuck with trading? Send me a DM—I’m here to help! Kris/ Mindbloome Exchange Trade What You See
NASDAQ:QMCO
by Mindbloome-Trading
Investing in Health: Reasons Why Novartis AG Stock Stands OutIn an era where health is wealth, and the global healthcare sector is booming like never before, savvy investors are looking for opportunities that promise growth and a meaningful impact on people’s lives. Enter Novartis AG—a powerhouse in pharmaceuticals that’s not only redefining treatments but also setting new standards in innovation and sustainability. A strong monthly demand imbalance at $97.13 per share has recently taken control. Expecting a decent reaction from this price level in the following weeks.
NYSE:NVSLong
by AlfonsoMoreno
NBIS Nebius Group Among My Top 10 Picks for 2025 | Price TargetNebius Group N.V. (NBIS) presents a compelling bullish case for a potential doubling of its stock price by the end of 2025, driven by several fundamental factors that highlight its growth trajectory within the rapidly expanding AI infrastructure market. NVIDIA Corporation (NVDA) has made a significant investment in Nebius Group N.V. (NBIS), contributing to a $700 million funding round aimed at expanding Nebius's AI infrastructure capabilities. This investment aligns with NVIDIA's strategic focus on enhancing its presence in the rapidly growing AI market. Explosive Revenue Growth: Nebius Group has demonstrated remarkable revenue growth, with Q3 2024 revenues reaching $43.3 million, representing a 1.7-fold increase compared to the previous quarter and a staggering 766% year-over-year increase. This surge is primarily driven by the company's core AI infrastructure business, which grew 2.7 times quarter-over-quarter and 6.5 times year-over-year. Analysts expect this momentum to continue, projecting annual revenues of approximately $731.96 million for 2025, reflecting a robust demand for AI-centric services and solutions. Strategic Investments in AI Infrastructure: The company is heavily investing in expanding its GPU cluster capabilities and data center capacity, with plans to allocate over $1 billion towards these initiatives. This strategic focus on enhancing AI infrastructure positions Nebius to capture significant market share as the global demand for AI technologies continues to rise. The annualized run-rate for its cloud revenue has already surpassed $120 million, indicating strong customer adoption and a growing client base that includes Fortune 500 companies. Strong Market Position and Competitive Advantage: Nebius Group is uniquely positioned within the AI infrastructure landscape, specializing in full-stack solutions that cater to developers and enterprises looking to leverage AI technologies. As businesses increasingly prioritize AI integration into their operations, Nebius's comprehensive offerings make it an attractive partner for organizations seeking to enhance their technological capabilities. The company’s ability to provide scalable solutions will be crucial as the demand for AI services expands. Healthy Financials and Cash Reserves: As of September 30, 2024, Nebius reported cash and cash equivalents totaling approximately $2.29 billion, providing a solid financial foundation to support its growth initiatives without excessive reliance on debt. This strong liquidity position allows Nebius to invest aggressively in technology and infrastructure while maintaining operational flexibility 14. Additionally, with gross margins projected to remain robust at around 55% in 2025, the company is well-positioned to improve profitability as revenues grow.
NASDAQ:NBISLong
by TopgOptions
2
Microsoft - We Will See A Correction!Microsoft ( NASDAQ:MSFT ) can actually create a correction: Click chart above to see the detailed analysis👆🏻 Microsoft is one of the strongest stocks over the past decade and also over the past couple of months, there was no clear sign of weakness. Therefore, it is actually not extremely likely that a correction will happen, but if it does, this will offer a long term texbook trading opportunity. Levels to watch: $420, $350 Keep your long term vision, Philip (BasicTrading)
NASDAQ:MSFTLong
by basictradingtv
8
Amazon - The +150% All Time High Breakout!Amazon ( NASDAQ:AMZN ) is hugging the previous all time high: Click chart above to see the detailed analysis👆🏻 Amazon has been moving sideways for almost four years, consolidating between support and the previous all time high. After retesting the resistance over and over again, it is just a matter of time until Amazon will break the previous all time high and start its next major bullish cycle. Levels to watch: $190, $500 Keep your long term vision, Philip (BasicTrading)
NASDAQ:AMZNLong
by basictradingtv
12
Micron Technology (MU): Is a Big Move Just Around the Corner?Good morning, trading family! Micron’s price has been moving between $92.90 resistance and $84.26 support, and it looks like a big move could be coming soon. Will we see a breakout to higher levels, or a pullback to retest support? This is one of those setups where being patient and watching how the price reacts at these levels can really pay off. Stay ready, and let’s tackle this opportunity together! Comment, like, follow, or send me a DM if you want a deeper analysis or more insights! Kris/Mindbloome Exchange Trade What You See
NASDAQ:MULong
by Mindbloome-Trading